Mustang Bio Q3 2026 Earnings Results & Report

Mustang Bio EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$140.00
• Beat/Miss: Beat by +$139.86
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 4 quarters

Mustang Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mustang Bio (NASDAQ:MBIO) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including cancer and rare genetic disorders. The company’s work centers on engineered immune-cell therapies designed to recognize and attack cancer cells, as well as gene therapies intended to address underlying disease causes.

Mustang’s development programs have included CAR T-cell therapies for hematologic malignancies and solid tumors. Its pipeline has featured MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell cancers, and programs targeting glioblastoma and other difficult-to-treat cancers. The company has also pursued gene-therapy candidates for rare diseases, including cerebral adrenoleukodystrophy.

Mustang Bio was established in 2015 and operates as a subsidiary of Fortress Biotech. Its research, clinical-development and manufacturing activities have been based primarily in the United States, with programs advanced through collaborations with academic and medical institutions. As a development-stage biotechnology company, its product candidates remain subject to clinical testing and regulatory review.